Applied BioCode files 510(k) for respiratory panel

By staff writers

September 13, 2019 -- Applied BioCode has submitted its Respiratory Pathogen Panel (RPP), which detects viruses and bacteria that cause upper respiratory infections, for 510(k) clearance with the U.S. Food and Drug Administration (FDA). It hopes to launch the product in December.

Indirect immunofluorescence microscopy of respiratory syncytial virus
Indirect immunofluorescence microscopy of RSV. Image courtesy of the U.S. Centers for Disease Control and Prevention/Dr. Craig Lyerla.

The BioCode RPP works with the company's MDx-3000 molecular system. It tests swabs from the back of the nose and throat for 20 common viruses and bacteria, including influenza A, influenza B, respiratory syncytial virus (RSV), and Chlamydia pneumoniae. Up to 188 samples may be processed during an eight-hour shift, according to the company.

The filing for FDA clearance of the respiratory panel was supported by a study of more than 2,600 samples evaluated prospectively at five geographically distributed laboratories in the U.S. This is the second panel developed for the MDx-3000 system. Applied BioCode's Gastrointestinal Pathogen Panel, which tests for 17 common bacteria, viruses, and parasites that cause infectious diarrhea, was cleared by the FDA in 2018.

The company is developing a third panel for detecting agents that cause sexually transmitted infections.

ASCP tackles hepatitis C, stool pathogens, and more in new test guidelines
The American Society for Clinical Pathology (ASCP) has released five new recommendations for appropriate lab test ordering, including advice against repeat...
McKesson set to deliver Qiagen's multipathogen test
McKesson is now a nonexclusive distributor of Qiagen's QIAstat-Dx syndromic system for respiratory and gastrointestinal diseases in smaller U.S. hospitals,...
ELISA blood test helps identify flu immunity
Researchers used an enzyme-linked immunosorbent assay (ELISA) blood test to assess immune response in people exposed to the H1N1 influenza A virus and...
InDevR's flu assay gets green light from FDA
InDevR's FluChip-8G Influenza A+B assay -- designed to identify virus subtypes -- has received 510(k) marketing clearance from the U.S. Food and Drug...

Copyright © 2019

Last Updated np 1/7/2020 10:49:18 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current